Swiss pharmaceutical company Novartis has started construction of a new manufacturing facility in Denton, Texas, as part of its previously announced $23 billion investment plan aimed at expanding research and production operations across the United States. The project, expected to be completed in 2028, will become the company’s first manufacturing site in Texas and its fifth radioligand therapy facility nationwide. According to the company, the plant is intended to improve access to cancer medicines for patients across the southern United States while strengthening its domestic supply chain. The expansion also supports Novartis’ wider strategy of increasing Radioligand Therapy Manufacturing capacity in the country.
Novartis CEO Vas Narasimhan said radioligand therapy “is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale.” He added, “Breaking ground in Denton further strengthens our U.S. supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.” The planned 46,000-square-foot facility is expected to create jobs in areas including advanced manufacturing, bioengineering, operations, and quality management, with the company saying the project will support economic activity in Denton and nearby communities.
Officials attending the groundbreaking ceremony included U.S. Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the U.S. Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth. Hagenbuch said, “I’m pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies.” He added that the investment reflects the advantages offered by the city’s workforce and access to the North Texas economy. The new Texas operation will join Novartis facilities already operating in New Jersey, Indiana, and California, alongside another site currently being developed in Florida. Together, the network is designed to support reliable delivery schedules for individualized cancer therapies that require highly coordinated production and distribution processes. The company said the expansion further strengthens its Radioligand Therapy Manufacturing network across the United States.
